Debiopharm International S.A.

• A randomized, placebo-controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with… Recruiting
  2024-516616-24-00 Phase III 16 countries OCTREOTIDE
• A phase 1 trial to study how safe and tolerable Lunresertib is, alone or in Combination with RP-3500 or Debio 0123, when administered in pat… Recruiting
  2023-510063-35-00 Phase I 3 countries 3-(2,6-DICHLOROPHENYL)-2,3-DIHYDRO-1-METHYL-7-[[3-METHYL-4-(1-METHYL-4-PIPERIDIN…
• A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy ad… Recruiting
  2024-519328-26-01 Phase I 1 country
• A Study of Debio 0123 in Combination with Temozolomide in Adult Participants with Recurrent or Progressive Glioblastoma and of Debio 0123 in… Recruiting
  2022-502156-31-00 Phase I/II 1 country 3-(2,6-DICHLOROPHENYL)-2,3-DIHYDRO-1-METHYL-7-[[3-METHYL-4-(1-METHYL-4-PIPERIDIN…
• A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended
  2024-511038-11-00 Phase II 7 countries DEGARELIX
• A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors Ended
  2023-504824-24-00 Phase I (Other) 1 country
• Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after… Ended
  2024-510980-40-00 Phase I (Other) 1 country
• A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors Ended
  2024-510984-52-00 Phase I 2 countries

Showing 1–8 of 8 trials